Skip to main content
. 2011 Jun 13;108(26):10562–10567. doi: 10.1073/pnas.1107559108

Fig. 3.

Fig. 3.

Mice expressing mutant L188Q SFTPC had greater lung fibrosis after i.t. bleomycin (Bleo). (A and B) Trichrome-stained lung sections from Dox-treated WT mice and L188Q SFTPC mice at 3 wk after 0.04 unit of i.t. bleomycin. (Magnification: ×100.) (C) Semiquantitative fibrosis scoring of trichrome-stained lung sections from WT and L188Q SFTPC mice at 3 wk after 0.04 unit of i.t. bleomycin. (n = 5 per group; *P < 0.05 compared with other groups.) Results are representative of three separate experiments. (D) Total lung collagen content from right lower lobe (RLL) based on hydroxyproline microplate assay at 3 wk after 0.04 unit of i.t. bleomycin or saline. (n = 4–6 per group for saline and 10 per group for bleomycin; *P < 0.05 compared with other groups.) (E) Semiquantitative scoring of S100A4+ lung fibroblasts on immunostained lung sections from WT and L188Q SFTPC mice at 3 wk after i.t. bleomycin. (n = 5 per group; *P < 0.05 compared with other groups.) (F) Semiquantitative scoring of αSMA+ lung fibroblasts on immunostained lung sections from WT and L188Q SFTPC mice at 3 wk after i.t. bleomycin. (n = 5 per group; *P < 0.05 compared with other groups.) (G) Static lung compliance in WT and L188Q SFTPC-expressing mice treated with Dox at 3 wk after i.t. bleomycin. (n = 3 per group for saline and 5–8 per group for bleomycin; *P < 0.05 between bleomycin-treated groups; #P < 0.001 compared with respective saline-treated group.) (H) Airway resistance in WT and L188Q SFTPC-expressing mice treated with Dox at 3 wk after i.t. bleomycin. Graphical data are presented as mean ± SEM.